



PRESS RELEASE

03 June 2026 13:00:00 CEST

AcouSort receives an order for AcouWash from a global leader in veterinary diagnostics

AcouSort AB today announced it has received an order from a global leader within veterinary diagnostics based in the US. The company has acquired an AcouWash system to be used in its R&D activities concerning separation of cells from blood samples as well as for separation of cells and microorganisms.

“We are very happy to initiate this collaboration with a leading player within the animal diagnostic field. We hope this is the start of a long-term and fruitful collaboration that may put AcouSorts technology to use supporting animal health,” said AcouSort’s CEO Dr. Torsten Freltoft.

The AcouWash will be used to improve and simplify the sample preparation workflow for samples used for product development purposes and to ensure that the sample quality is consistent and not dependent on user variations. The company is active within development of diagnostic solutions for companion animals, but also within the livestock and equine markets.

Revenues generated for this order will be USD 59,000.

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com

ABOUT ACOUSORT

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Tapper Partners AB.